CXCL13 and myeloid sarcoma: Furthermore, CXCL13 levels have been found to correlate with disease severity measured using the EDSS scale, as well as T2 lesions, intrathecal immunoglobulin production, oligoclonal bands (OCBs) and lymphocytes, indicating that it can be used as a prognostic marker in MS (Krumbholz et al., 2006; Khademi et al., 2011; Axelsson et al., 2013; Lindén et al., 2013; Ferraro et al., 2015; Håkansson et al., 2018).